DOI QR코드

DOI QR Code

Meta-analysis of the MDM2 T309G Polymorphism and Gastric Cancer Risk

  • Song, Bo (Department of General Surgery, The Fourth Affiliated Hospital of Kunming Medical University) ;
  • Duan, Zhong-Yu (College of International Education, Yunnan University of Traditional Chinese Medicine) ;
  • Zhong, Yun-Hua (Department of Cadres Health Care, The First People's Hospital of Yunnan Province) ;
  • Lei, Na (School of Basic Medical Sciences, Yunnan University of Traditional Chinese Medicine) ;
  • Yang, Yu-Qing (School of Basic Medical Sciences, Yunnan University of Traditional Chinese Medicine) ;
  • Luo, Kai-Yuan (Department of General Surgery, The Fourth Affiliated Hospital of Kunming Medical University)
  • Published : 2013.11.30

Abstract

Background: Mdm2 binds to the amino-terminus of p53 to induce its degradation and a single nucleotide polymorphism in the MDM2 promoter region (T309G) has been reported to increase the risk of several carcinomas, such as gastric cancer. However, the results of published studies to analyze the association between MDM2 T309G and gastric cancer havve often conflicted. Methods: To better illustrate the filiation between MDM2 T309G and gastric cancer, we performed a meta-analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of the relationship. The pooled ORs were performed for 4 models, additive, recessive, co-dominant model, and dominant. Results: Nine published case-control studies including 3,225 gastric cancer cases and 4,118 controls were identified. The MDM2 T309G polymorphism was associated with a significantly increased risk of gastric cancer risk when all studies were pooled into the meta-analysis (GG versus TT, OR=1.57; 95%CI=1.57-2.12; p=0.003) and GG versus GT/TT, OR=1.52; 95%CI=1.217-1.90; p<0.001). Furthermore, Egger's test did not show any evidence of publication bias (P = 0.608 for GG versus TT). Conclusion: Our results suggest that the MDM2 T309G polymorphism is indeed associated with a significantly increased risk of gastric cancer.

Keywords

Gastric cancer;Mdm2 T309G;meta-analysis

References

  1. Alakus H, Monig SP, Warnecke-Eberz U, et al (2009). Association of the GNAS1 T393C polymorphism with tumor stage and survival in gastric cancer. World J Gastroenterol, 15, 6061-7. https://doi.org/10.3748/wjg.15.6061
  2. Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the Mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602. https://doi.org/10.1016/j.cell.2004.11.022
  3. Brosh R, Rotter V (2009). When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer, 9, 701-13. https://doi.org/10.1038/nrc2693
  4. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  5. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  6. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  7. Levine AJ, Oren M (2009). The first 30 years of p53: growing ever more complex. Nat Rev Cancer, 9, 749-58. https://doi.org/10.1038/nrc2723
  8. Li X, Yang XX, Hu NY, et al (2011). A risk-associated single nucleotide polymorphism of SMAD7 is common to colorectal, gastric, and lung cancers in a Han Chinese population. Mol Biol Rep, 38, 5093-7. https://doi.org/10.1007/s11033-010-0656-3
  9. Ma Y, Bian J, Cao H (2013). Mdm2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PLoS One, 8, e56918. https://doi.org/10.1371/journal.pone.0056918
  10. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  11. Ohmiya N, Taguchi A, Mabuchi N, et al (2006). Mdm2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 24, 4434-40. https://doi.org/10.1200/JCO.2005.04.1459
  12. Pan X, Li Y, Feng J, et al (2013). A functional polymorphism T309G in Mdm2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients. BMC Cancer, 13, 126. https://doi.org/10.1186/1471-2407-13-126
  13. Saeki N, Ono H, Sakamoto H, Yoshida T (2013). Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study. Cancer Sci, 104, 1-8. https://doi.org/10.1111/cas.12042
  14. Shibata T, Arisawa T, Tahara T, et al (2009). Selenoprotein S (SEPS1) gene -105G>A promoter polymorphism influences the susceptibility to gastric cancer in the Japanese population. BMC Gastroenterol, 9, 2. https://doi.org/10.1186/1471-230X-9-2
  15. Xu M, Tao G, Kang M, et al (2013). A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PLoS One, 8, e60080. https://doi.org/10.1371/journal.pone.0060080
  16. Yang M, Guo Y, Zhang X, et al (2007). Interaction of P53 Arg72Pro and Mdm2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 28, 1996-2001. https://doi.org/10.1093/carcin/bgm168
  17. Yang Z, Shu X, Chen L, et al (2012). Expression of p53-Mdm2 feedback loop related proteins in different gastric pathologies in relation to Helicobacter pylori infection: implications in gastric carcinogenesis. Clin Res Hepatol Gastroenterol, 36, 235-43. https://doi.org/10.1016/j.clinre.2011.11.009
  18. Zhang Q, Ma YY, Wang HJ, et al (2013). Meta-analysis of the association between P53 codon 72 polymorphisms and gastric cancer. J Surg Oncol, 107, 360-6. https://doi.org/10.1002/jso.23233
  19. Zhao P, Dai M, Chen W, Li N (2010). Cancer trends in China. Jpn J Clin Oncol, 40, 281-5. https://doi.org/10.1093/jjco/hyp187
  20. Zou TH, Wang ZH, Fang JY (2013). Positive association between Toll-like receptor 4 gene +896A/G polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Tumour Biol, 34, 2441-50. https://doi.org/10.1007/s13277-013-0795-y

Cited by

  1. Pemetrexed is Mildly Active with Good Tolerability in Treating Patients with Gastric Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7137
  2. Effects of p53 Codon 72 and MDM2 SNP309 Polymorphisms on Gastric Cancer Risk among the Iranian Population vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7413
  3. Goseki Grade and Tumour Location Influence Survival of Patients with Gastric Cancer vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1429
  4. Lack of Association of the MDR1 C3435T Polymorphism with Susceptibility to Gastric Cancer and Peptic Ulcer: a Systemic Review and Meta-analysis vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3021
  5. Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population vol.32, pp.1, 2015, https://doi.org/10.1007/s12032-014-0401-1